Senti Biosciences Holdings financials
$0.3075−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0K | $16.0K | $22.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $338.0K |
| Gross profit | $17.0K | $16.0K | $22.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $338.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | 100.0% |
| Operating income | -$14.5M | -$4.6M | -$18.6M | -$16.9M | -$16.8M | -$16.4M | -$16.2M | -$15.2M | -$13.4M | -$16.3M | -$18.7M | -$43.9M |
| Net income | -$12.8M | -$4.2M | -$14.5M | -$18.1M | -$14.7M | -$14.1M | -$3.1M | -$28.9M | -$11.2M | -$12.1M | -$18.7M | -$14.9M |
| Net margin | −75000.0% | −26381.3% | −65759.1% | — | — | — | — | — | — | — | — | −4415.1% |
| Diluted EPS | $-0.41 | $-0.14 | $-0.52 | $-0.69 | $-0.56 | $-1.41 | $-0.67 | $-6.31 | $-2.45 | $-2.65 | $-1.50 | $-3.36 |
| EBITDA | -$13.8M | -$10.8M | -$12.7M | -$16.0M | -$15.9M | -$15.5M | -$14.9M | -$14.3M | -$12.4M | -$15.3M | -$17.4M | -$16.8M |
| Operating cash flow | -$14.2M | -$7.5M | -$6.9M | -$9.4M | -$13.1M | -$14.1M | -$13.5M | -$7.9M | -$8.3M | -$11.7M | -$7.0M | -$15.4M |
| Free cash flow | -$14.2M | -$7.5M | -$6.9M | -$9.4M | -$13.3M | -$14.1M | -$13.5M | -$7.9M | -$8.3M | -$11.7M | -$7.0M | -$17.2M |
| Diluted shares | 31.1M | 31.0M | 27.6M | 26.2M | 26.1M | 10.0M | 4.7M | 4.6M | 4.6M | 4.6M | 12.5M | 4.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.5M | $8.9M | $16.4M | $12.2M | $21.6M | $33.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $4.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $33.1M | $38.2M | $51.2M | $52.7M | $68.5M | $82.8M |
| Total liabilities | $36.5M | $35.7M | $45.6M | $44.6M | $43.9M | $44.9M |
| Shareholders' equity | -$3.4M | $2.6M | $5.6M | $8.1M | $24.7M | $37.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology